Answers are grounded in this paper and cite their sources.
Antiplatelet medications currently on the market interfere with one or more phases in the platelet release and aggregation process, leading to a meaningful decrease in thrombosis risk that cannot be separated from an elevated risk of bleeding. Understanding that under physiological conditions, 1011 platelets are created daily-a quantity that can rise up to 10-fold during times of greater need—is crucial when thinking about antiplatelet medications.
No takes yet. Share an insight, caveat, or question.
Sinha et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: